000131783 001__ 131783
000131783 005__ 20240229105013.0
000131783 0247_ $$2doi$$a10.1093/neuonc/nox149
000131783 0247_ $$2pmid$$apmid:29016894
000131783 0247_ $$2pmc$$apmc:PMC5761525
000131783 0247_ $$2ISSN$$a1522-8517
000131783 0247_ $$2ISSN$$a1523-5866
000131783 0247_ $$2altmetric$$aaltmetric:23450378
000131783 037__ $$aDKFZ-2018-00080
000131783 041__ $$aeng
000131783 082__ $$a610
000131783 1001_ $$aKarremann, Michael$$b0
000131783 245__ $$aDiffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
000131783 260__ $$aOxford$$bOxford Univ. Press$$c2018
000131783 3367_ $$2DRIVER$$aarticle
000131783 3367_ $$2DataCite$$aOutput Types/Journal article
000131783 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521453675_7049
000131783 3367_ $$2BibTeX$$aARTICLE
000131783 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000131783 3367_ $$00$$2EndNote$$aJournal Article
000131783 520__ $$aThe novel entity of 'diffuse midline glioma, H3 K27M-mutant' has been defined in the 2016 revision of the World Health Organization (WHO) classification of tumors of the central nervous system (CNS). Tumors of this entity arise in CNS midline structures of predominantly pediatric patients and are associated with an overall dismal prognosis. They are defined by K27M mutations in H3F3A or HIST1H3B/C, encoding for histone 3 variants H3.3 and H3.1, respectively, which are considered hallmark events driving gliomagenesis.Here, we characterized 85 centrally reviewed diffuse gliomas on midline locations enrolled in the nationwide pediatric German HIT-HGG registry regarding tumor site, histone 3 mutational status, WHO grade, age, sex, and extent of tumor resection.We found 56 H3.3 K27M-mutant tumors (66%), 6 H3.1 K27M-mutant tumors (7%), and 23 H3-wildtype tumors (27%). H3 K27M-mutant gliomas shared an aggressive clinical course independent of their anatomic location. Multivariate regression analysis confirmed the significant impact of the H3 K27M mutation as the only independent parameter predictive of overall survival (P = 0.009). In H3 K27M-mutant tumors, neither anatomic midline location nor histopathological grading nor extent of tumor resection had an influence on survival.These results substantiate the clinical significance of considering diffuse midline glioma, H3 K27M-mutant, as a distinct entity corresponding to WHO grade IV, carrying a universally fatal prognosis.
000131783 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000131783 588__ $$aDataset connected to CrossRef, PubMed,
000131783 7001_ $$aGielen, Gerrit H$$b1
000131783 7001_ $$aHoffmann, Marion$$b2
000131783 7001_ $$aWiese, Maria$$b3
000131783 7001_ $$aColditz, Niclas$$b4
000131783 7001_ $$aWarmuth-Metz, Monika$$b5
000131783 7001_ $$aBison, Brigitte$$b6
000131783 7001_ $$aClaviez, Alexander$$b7
000131783 7001_ $$avan Vuurden, Dannis G$$b8
000131783 7001_ $$avon Bueren, André O$$b9
000131783 7001_ $$aGessi, Marco$$b10
000131783 7001_ $$aKühnle, Ingrid$$b11
000131783 7001_ $$aHans, Volkmar H$$b12
000131783 7001_ $$aBenesch, Martin$$b13
000131783 7001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, Dominik$$b14$$udkfz
000131783 7001_ $$aKortmann, Rolf-Dieter$$b15
000131783 7001_ $$aWaha, Andreas$$b16
000131783 7001_ $$aPietsch, Torsten$$b17
000131783 7001_ $$aKramm, Christof M$$b18
000131783 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/nox149$$gVol. 20, no. 1, p. 123 - 131$$n1$$p123 - 131$$tNeuro-Oncology$$v20$$x1523-5866$$y2018
000131783 909CO $$ooai:inrepo02.dkfz.de:131783$$pVDB
000131783 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000131783 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000131783 9141_ $$y2018
000131783 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000131783 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000131783 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2015
000131783 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000131783 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000131783 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000131783 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000131783 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000131783 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000131783 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000131783 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2015
000131783 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000131783 980__ $$ajournal
000131783 980__ $$aVDB
000131783 980__ $$aI:(DE-He78)B062-20160331
000131783 980__ $$aUNRESTRICTED